PMA device
Misago Peripheral Self-Expanding Stent System
Terumo Medical Corporation · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision May 22, 2015, newest Mar 8, 2017Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
4
Naming "Misago"
MAUDE reports
144
Brand "Misago", since 2015
PubMed studies
27
Mentioning "Misago"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Misago Peripheral Self-Expanding Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- MISAGO PERIPHERAL SELF-EXPANDING STENT SYSTEMPMA supplement
P140002-S002 · Decided Mar 8, 2017 · 306 days after receipt · Normal 180 Day Track
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Misago", any status and sponsor, newest update first.
Terumo Medical CorporationPublic (4543.T)
NCT02793492 · 75 participants · Start Aug 30, 2022 · Primary completion Feb 24, 2025
Device: Misago® RX Self-expanding Peripheral Stent · For: Iliac Artery Stenosis
Sites: Thornton, Colorado; Gainesville, Florida; Jacksonville, Florida · 9 sites in all
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Misago", and for the whole product code for context.
This brand
144 reports: 73 malfunction, 70 injury, 1 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- R2P MISAGOMalfunction
9681834-2026-00191 · Received Sep 8, 2026 · Event dated Aug 5, 2026
Device type: Stent, Superficial Femoral Artery (NIP)
Device problem as coded: Material Frayed; Material Deformation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- MISAGO RX Self Expanding Peripheral StemTerminated
Z-0669-2017 · Started Aug 4, 2016
Reason given: During recent routine testing, the MISAGO Peripheral Stent was found not to conform to product specification related to stent diameter at the proximal/distal ends and/or the shape of the stent.
Cause as FDA categorized it: Device Design · Device type: Stent, Superficial Femoral Artery (NIP)
Published research
The most relevant PubMed records for "Misago"[tiab]. The summary above synthesizes these.
- Heterogeneous vascular response after implantation of bare nitinol self-expanding stents in the swine femoropopliteal artery.
Kawarada O, Otsuka F, Miki K, et al. · Cardiovasc Interv Ther · 2023
- Comparative 2-year outcomes of the Misago stent versus other self-expandable nitinol stents for the endovascular treatment of aortoiliac disease.
Haraguchi T, Masanaga T, Fujita T, et al. · J Cardiovasc Surg (Torino) · 2023Observational Study
- A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y, Sauguet A, Desgranges P, et al. · JACC Cardiovasc Interv · 2020Comparative Study, Multicenter Study
- Infundibulocystic Squamous Cell Carcinoma.
Kim SM, Kim H, Kim HS, et al. · Ann Dermatol · 2015Case Reports
- Three-year clinical outcomes of the Misago stent via transradial intervention for aorto-iliac arterial disease.
Tsuchida Y, Hayakawa N, Miwa H, et al. · Heart Vessels · 2025Observational Study
- Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
Gouëffic Y, Kaladji A, Guyomarch B, et al. · Trials · 2014Comparative Study, Multicenter Study
- A method of assessing peripheral stent abrasiveness under cyclic deformations experienced during limb movement.
Keiser C, Maleckis K, Struczewska P, et al. · Acta Biomater · 2022Research Support, N.I.H., Extramural
- Comparison of second-generation stents for application in the superficial femoral artery: an in vitro evaluation focusing on stent design.
Müller-Hülsbeck S, Schäfer PJ, Charalambous N, et al. · J Endovasc Ther · 2010Comparative Study, Research Support, Non-U.S. Gov't
- Retrospective Multicenter Comparison of S.M.A.R.T. CONTROL and MISAGO Stents in Treatment of Femoropopliteal Lesions.
Suzuki K, Takahara M, Shintani Y, et al. · J Vasc Interv Radiol · 2016Comparative Study, Multicenter Study
- Deformation of the Femoropopliteal Segment: Effect of Stent Length, Location, Flexibility, and Curvature.
Ní Ghriallais R, Heraty K, Smouse B, et al. · J Endovasc Ther · 2016Comparative Study, Research Support, Non-U.S. Gov't
- MISAGO 1: first-in-man clinical trial with Misago nitinol stent.
Schulte KL, Müller-Hülsbeck S, Cao P, et al. · EuroIntervention · 2010Comparative Study, Multicenter Study
- Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
Miura T, Miyashita Y, Soga Y, et al. · Circ Cardiovasc Interv · 2018Comparative Study, Multicenter Study
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.